Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .
Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome.
Aggressive treatment with high-dose atorvastatin reduces more effectively the incidence of cardiovascular events than moderate statin therapy . The mechanism of this benefit has not been fully eluci date d. In order to know the potential effects of statin treatment on the protein expression of circulating monocytes in acute coronary syndrome ( ACS ) patients , a proteomic analysis of these cells was carried out by 2-DE and MS . Twenty-five patients with non-ST-elevation acute coronary syndrome ( NSTEACS ) were r and omized , the fourth day after admission , to receive ATV 80 mg/dL ( n = 14 ) or conventional treatment ( CT ) ( n = 11 ) , for two months . Blood was withdrawn at the end of the treatment , and monocytes were extracted for proteomic analysis and their protein expression patterns determined . Age , sex , total cholesterol , LDL , HDL , triglycerides , body mass index , presence of hypertension , diabetes , and smoking status were not significantly different between the two groups of patients . The expression of 20 proteins was modified by intensive ATV . Among the most relevant results st and out the normalization by intensive ATV treatment of the expression of proteins that modulate inflammation and thrombosis such as protein disulfide isomerase ER60 ( PDI ) , Annexin I , and prohibitin , or that have other protective effects as HSP-70 . Thus , this approach shed light at the molecular level of the beneficial mechanisms of anti-atherothrombotic drugs
Based on moderate quality evidence , due to concerns about risk of bias and imprecision , initiation of statin therapy within 14 days following ACS does not reduce death , myocardial infa rct ion , or stroke up to four months , but reduces the occurrence of unstable angina at four months following ACS .
Serious side effects were rare
BACKGROUND The early period following the onset of acute coronary syndrome ( ACS ) represents a critical stage of coronary heart disease , with a high risk of recurrent events and deaths .
The short-term effects of early treatment with statins on patient-relevant outcomes in patients suffering from ACS are unclear .
This is an up date of a review previously published in 2011 .
OBJECTIVES To assess the effects , both harms and benefits , of early administered statins in patients with ACS , in terms of mortality and cardiovascular events .